PBH Prestige Consumer Healthcare (PBH) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001295947
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
159
13F, latest reported quarter
What the filings say about PBH
Insiders, 180 days
-$120.4K net sold
1 seller · 0% of sales under a 10b5-1 plan
Prestige Consumer Healthcare insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Prestige Consumer Healthcare Inc. insiders sold a net $120.4K of stock across 54 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on May 7, 2026.
- The trade is 0.8% of the 41,810 shares held after it.
- No other insider sold within 30 days.
- 159 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Senior VP Operations Zerillo Jeffrey sold about $18.4K of PBH on May 11, 2026; 159 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on May 5, 2026.
- The trade is 0.7% of the 42,161 shares held after it.
- No other insider sold within 30 days.
- 159 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Senior VP Operations Zerillo Jeffrey sold about $16.6K of PBH on May 7, 2026; 159 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Feb 11, 2026.
- The trade is 2.8% of the 42,820 shares held after it.
- No other insider sold within 30 days.
- 159 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Senior VP Operations Zerillo Jeffrey sold about $66.4K of PBH on May 5, 2026; 159 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Feb 11, 2026.
- The trade is 0.8% of the 44,334 shares held after it.
- No other insider sold within 30 days.
- 159 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Senior VP Operations Zerillo Jeffrey sold about $19.1K of PBH on May 5, 2026; 159 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Dec 1, 2025.
- The trade is 2.4% of the 41,048 shares held after it.
- No other insider sold within 30 days.
- 159 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Senior VP Operations Zerillo Jeffrey sold about $65.9K of PBH on Feb 11, 2026; 159 funds added in the latest 13F quarter.54 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$120.4K over 180 days
more than 55% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
159 funds bought in last quarter
more than 84% of Pharma & Biotech
Revenue
-4.3% year over year
below 61% of Pharma & Biotech
Margin
17.5% net margin
more than 86% of Pharma & Biotech
Buybacks
$156.3M repurchased, FY to 2026-03-31
more than 73% of Pharma & Biotech
Short interest
9.9% of the float short (float per yahoo 2026-10-26) · 6.6 days to cover · settled 2026-09-30
more than 71% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 4 in the prior 90
Why it matters
The absence is the signal: 4 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch PBH
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-23.1%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PBH: institutional holders (13F)
13F holdings, latest reported quarter
7,831,333 sh
$370.2M
4,868,711 sh
$230.1M
2,825,340 sh
$133.6M
2,661,291 sh
$125.8M
2,331,821 sh
$110.2M
Congress trades in PBH
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
PBH planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
PBH mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ariel Focus Fund
$3.2M position · as of 2026-06-30
3.6%
Brandes Small Cap Value Fund
$19.9M position · as of 2026-06-30
3.1%
Virtus KAR Small-Cap Value Fund
$17.4M position · as of 2026-06-30
2.9%
Ariel Fund
$80.5M position · as of 2026-06-30
2.8%
Invesco Pharmaceuticals ETF
$12.9M position · as of 2026-07-31
2.7%
Virtus KAR Small-Cap Value Series
$1.4M position · as of 2026-06-30
2.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Lombardi
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$6.0M
$825.5K
$1.6M
+34%
-30%
2024
$6.2M
$7.6M
$1.9M
+95%
+14%
2023
$5.8M
$9.7M
$1.4M
+65%
-0%
2022
$5.6M
$9.5M
$1.3M
+42%
-12%
2021
$6.0M
$9.9M
$1.5M
+20%
+0%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $120.4K sold by insiders over 180 days, 159 funds added last quarter. Each figure is a federal filing, dated the day it went public.
PBH financials
Revenue growth
-4.3%
XBRL, annual
Net margin
17.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.1B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM PBH
| FY Mar 2026 | $1.1B |
| FY Mar 2025 | $1.1B |
| FY Mar 2024 | $1.1B |
| FY Mar 2023 | $1.1B |
| FY Mar 2022 | $1.1B |
| Jun 2026 | $265.7M |
| Mar 2026 | $281.6M |
| Dec 2025 | $283.4M |
| Sep 2025 | $274.1M |
| Jun 2025 | $249.5M |
| Mar 2025 | $296.5M |
| Dec 2024 | $290.3M |
| Sep 2024 | $283.8M |
At each fiscal year end
Single quarter
Net margin, TTM
+15.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM PBH
| FY Mar 2026 | +17.5% |
| FY Mar 2025 | +18.9% |
| FY Mar 2024 | +18.6% |
| FY Mar 2023 | -7.3% |
| FY Mar 2022 | +18.9% |
| Jun 2026 | +11.0% |
| Mar 2026 | +19.1% |
| Dec 2025 | +16.5% |
| Sep 2025 | +15.4% |
| Jun 2025 | +19.0% |
| Mar 2025 | +16.9% |
| Dec 2024 | +21.0% |
| Sep 2024 | +19.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$235.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM PBH
| FY Mar 2026 | $246.4M |
| FY Mar 2025 | $243.3M |
| FY Mar 2024 | $239.4M |
| FY Mar 2023 | $221.9M |
| FY Mar 2022 | $250.3M |
| Jun 2026 | $67.1M |
| Mar 2026 | $37.6M |
| Dec 2025 | $75.3M |
| Sep 2025 | $55.4M |
| Jun 2025 | $78.2M |
| Mar 2025 | $58.4M |
| Dec 2024 | $63.5M |
| Sep 2024 | $67.8M |
At each fiscal year end
Single quarter
Debt to equity
1.05x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity PBH
| FY Mar 2026 | 0.53x |
| FY Mar 2025 | 0.54x |
| FY Mar 2024 | 0.69x |
| FY Mar 2023 | 0.93x |
| FY Mar 2022 | 0.94x |
| Jun 2026 | 1.05x |
| Mar 2026 | 0.53x |
| Dec 2025 | 0.56x |
| Sep 2025 | 0.54x |
| Jun 2025 | 0.54x |
| Mar 2025 | 0.54x |
| Dec 2024 | 0.56x |
| Sep 2024 | 0.62x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.12x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt PBH
| FY Mar 2026 | 0.26x |
| FY Mar 2025 | 0.25x |
| FY Mar 2024 | 0.22x |
| FY Mar 2023 | 0.17x |
| FY Mar 2022 | 0.18x |
| Jun 2026 | 0.12x |
| Mar 2026 | 0.26x |
| Dec 2025 | 0.27x |
| Sep 2025 | 0.27x |
| Jun 2025 | 0.28x |
| Mar 2025 | 0.25x |
| Dec 2024 | 0.26x |
| Sep 2024 | 0.25x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+9.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity PBH
| FY Mar 2026 | +10.2% |
| FY Mar 2025 | +12.3% |
| FY Mar 2024 | +13.5% |
| FY Mar 2023 | -5.4% |
| FY Mar 2022 | +14.0% |
| Jun 2026 | +9.1% |
| Mar 2026 | +10.2% |
| Dec 2025 | +10.3% |
| Sep 2025 | +11.3% |
| Jun 2025 | +12.0% |
| Mar 2025 | +12.3% |
| Dec 2024 | +12.6% |
| Sep 2024 | +12.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+4.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PBH
| FY Mar 2026 | +5.5% |
| FY Mar 2025 | +6.4% |
| FY Mar 2024 | +6.3% |
| FY Mar 2023 | -2.3% |
| FY Mar 2022 | +5.8% |
| Jun 2026 | +4.3% |
| Mar 2026 | +5.5% |
| Dec 2025 | +5.5% |
| Sep 2025 | +5.9% |
| Jun 2025 | +6.3% |
| Mar 2025 | +6.4% |
| Dec 2024 | +6.4% |
| Sep 2024 | +6.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+5.2%
operating income after a 32.6% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital PBH
| FY Mar 2026 | +7.2% |
| FY Mar 2025 | +8.0% |
| FY Mar 2024 | +8.4% |
| FY Mar 2023 | n/a |
| FY Mar 2022 | +7.9% |
| Jun 2026 | +5.2% |
| Mar 2026 | +7.2% |
| Dec 2025 | +6.7% |
| Sep 2025 | +6.9% |
| Jun 2025 | +7.7% |
| Mar 2025 | +8.0% |
| Dec 2024 | +8.3% |
| Sep 2024 | +8.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+7.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PBH
| FY Mar 2026 | +9.3% |
| FY Mar 2025 | +10.4% |
| FY Mar 2024 | +10.7% |
| FY Mar 2023 | -0.7% |
| FY Mar 2022 | +9.7% |
| Jun 2026 | +7.5% |
| Mar 2026 | +9.3% |
| Dec 2025 | +9.8% |
| Sep 2025 | +10.2% |
| Jun 2025 | +10.3% |
| Mar 2025 | +10.4% |
| Dec 2024 | +10.3% |
| Sep 2024 | +10.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
13.49x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing PBH
| FY Mar 2026 | 15.16x |
| FY Mar 2025 | 19.99x |
| FY Mar 2024 | 17.40x |
| FY Mar 2023 | n/a |
| FY Mar 2022 | 13.10x |
| Jun 2026 | 13.24x |
| Mar 2026 | 15.16x |
| Dec 2025 | 16.28x |
| Sep 2025 | 15.45x |
| Jun 2025 | 18.70x |
| Mar 2025 | 19.99x |
| Dec 2024 | 18.29x |
| Sep 2024 | 17.54x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$4.2B
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value PBH
| FY Mar 2026 | $3.7B |
| FY Mar 2025 | $5.2B |
| FY Mar 2024 | $4.7B |
| FY Mar 2023 | $4.4B |
| FY Mar 2022 | $4.1B |
| Jun 2026 | $4.2B |
| Mar 2026 | $3.7B |
| Dec 2025 | $3.9B |
| Sep 2025 | $3.9B |
| Jun 2025 | $4.8B |
| Mar 2025 | $5.2B |
| Dec 2024 | $4.8B |
| Sep 2024 | $4.6B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+10.3%
TTM free cash flow over market value at close 2026-10-26
FCF yield PBH
| FY Mar 2026 | +8.8% |
| FY Mar 2025 | +5.7% |
| FY Mar 2024 | +6.6% |
| FY Mar 2023 | +7.1% |
| FY Mar 2022 | +9.4% |
| Jun 2026 | +10.5% |
| Mar 2026 | +8.8% |
| Dec 2025 | +9.0% |
| Sep 2025 | +8.3% |
| Jun 2025 | +6.8% |
| Mar 2025 | +5.7% |
| Dec 2024 | +6.4% |
| Sep 2024 | +7.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -16%, PEG needs growth
PEG, trailing PBH
| FY Mar 2026 | n/a |
| FY Mar 2025 | 6.41x |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | 0.54x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | 4.25x |
| Mar 2025 | 6.41x |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-03 | 2025-03 | 2024-03 | 2023-03 | |
|---|---|---|---|---|
| Revenue | $1.1B | $1.1B | $1.1B | $1.1B |
| Gross profit | $595.6M | $634.5M | $624.4M | $625.3M |
| Operating income | $309.4M | $336.8M | $342.4M | -$22.4M |
| Net income | $190.3M | $214.6M | $209.3M | -$82.3M |
| EPS (diluted) | 3.91 | 4.29 | 4.17 | -1.65 |
| Operating cash flow | $257.6M | $251.5M | $248.9M | $229.7M |
| Cash | $63.9M | $97.9M | $46.5M | $58.5M |
| Long-term debt | $994.0M | $992.4M | $1.1B | $1.3B |
| Buybacks | $156.3M | $51.5M | $25.0M | $50.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
PBH Stock Sonar score 6/7 axes
Find similar shapesComparePBH ranks highest on institutional and government (84th percentile) and profitability (69th), and lowest on insider conviction (26th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
PBH filings, in plain words
Are Prestige Consumer Healthcare insiders buying or selling PBH?
In the 180 days to 2026-10-28, Prestige Consumer Healthcare insiders were net sellers, a net $120.4K across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-28, Prestige Consumer Healthcare insiders were net sellers of PBH, a net $120.4K across purchases and sales reported on Form 4 by 1 seller. None of the 4 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
